¼¼°èÀÇ ¾ËÆÄ ¸ÞÆ¿µµÆÄ ½ÃÀå º¸°í¼­(2024³â)
Alpha (a) Methyldopa Global Market Report 2024
»óǰÄÚµå : 1546392
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,000 £Ü 6,855,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,283,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,711,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾ËÆÄ ¸ÞÆ¿µµÆÄ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2028³â¿¡´Â CAGR 10.3%·Î 151¾ï 4,000¸¸ ´Þ·¯·Î ¼ºÀåÇÕ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº Áø´Ü ±â¼ú Çâ»ó, °øÁß º¸°Ç Ä·ÆäÀÎ È®´ë, ¿¬±¸ ÀÚ±Ý Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¹ß, °íÇ÷¾Ð »ç·Ê Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ ±â°£ Áß ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¾à¹°Àü´Þ ½Ã½ºÅÛ ¹ßÀü, ¹ÙÀÌ¿ÀÀǾàǰ Çõ½Å, ÀÓ»ó½ÃÇè ¹æ¹ý °³¹ß, µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç ÅëÇÕ, ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ ÀΰøÁö´É Àû¿ë µîÀÌ ÀÖ½À´Ï´Ù.

¾ËÆÄ ¸ÞÆ¿µµÆÄ ½ÃÀåÀº °íÇ÷¾Ð ȯÀÚ Áõ°¡·Î ÀÎÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ËÆÄ ¸ÞÆ¿µµÆÄ´Â Ç÷¾×³» ƯÁ¤ È­Çй°ÁúÀ» ³·Ãß°í Ç÷°ü ÀÌ¿ÏÀ» ÃËÁøÇϸç Ç÷¾ÐÀ» ³·ÃãÀ¸·Î½á °íÇ÷¾ÐÀ» È¿°úÀûÀ¸·Î Ä¡·áÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ½ÉÀå Àç´ÜÀÌ 2024³â 1¿ù¿¡ º¸°íÇÑ ¹Ù¿¡ µû¸£¸é È£ÁÖ ¼ºÀÎÀÇ ¾à 23%°¡ °íÇ÷¾ÐÀ» ¾Î°í ÀÖÀ¸¸ç, ³²¼º(25%)ÀÌ ¿©¼º(22%)º¸´Ù ´õ ³ôÀº À¯º´·üÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ËÆÄ ¸ÞÆ¿µµÆÄ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾ËÆÄ ¸ÞÆ¿µµÆÄ ½ÃÀåÀº Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ËÆÄ ¸ÞÆ¿µµÆÄ´Â °íÇ÷¾Ð °ü¸®¿¡ ³Î¸® »ç¿ëµÇ´Â Á¦³×¸¯ ÀǾàǰÀ¸·Î ƯÈ÷ ÀÓ»êºÎ¿Í °°Àº ±×·ì¿¡ ÇýÅÃÀ» Á¦°øÇÕ´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹Àº 2023³â Á¦³×¸¯ ÀǾàǰÀÌ ¹Ì±¹ ó¹æ¾à ½ÃÀåÀÇ ¾à 90%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿µ±¹, È£ÁÖ, Áß±¹, µ¶ÀÏ µî ±¹°¡¿¡¼­µµ Á¦³×¸¯ ÀǾàǰÀÌ ³Î¸® äÅõǰí ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¦³×¸¯ ÀǾàǰ¿¡ ´ëÇÑ ¼±È£´Â ¾ËÆÄ ¸ÞÆ¿µµÆÄ ½ÃÀåÀ» °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¼ºÀå

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå °æÀï º¥Ä¡¸¶Å·

Á¦33Àå °æÀï ´ë½Ãº¸µå

Á¦34Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦35Àå ÇâÈÄ Àü¸Á°ú ÀáÀçÀû ºÐ¼®

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Alpha methyldopa, often written as a-methyldopa, is a medication primarily used to manage high blood pressure (hypertension) by affecting the central nervous system. It lowers blood pressure and reduces certain chemicals in the body that narrow blood vessels. Alpha methyldopa is also prescribed to treat specific conditions during pregnancy, such as preeclampsia.

The main types of alpha (a) methyldopa include oral and intravenous formulations. Oral alpha methyldopa is taken by mouth and acts as a central alpha-2 adrenergic agonist to treat high blood pressure. It is available in various purity levels, such as purity >=98% and purity >=99%, and has additional applications in conditions such as parkinsonism and hepatic coma.

The alpha (a) methyldopa market research report is one of a series of new reports from The Business Research Company that provides alpha (a) methyldopa market statistics, including the alpha (a) methyldopa industry's global market size, regional shares, competitors with an alpha (a) methyldopa market share, detailed alpha (a) methyldopa market segments, market trends and opportunities, and any further data you may need to thrive in the alpha (a) methyldopa industry. This alpha (a) methyldopa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The alpha (a) methyldopa market size has grown rapidly in recent years. It will grow from $9.31 billion in 2023 to $10.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to several factors, increasing awareness about hypertension, a focus on managing chronic diseases, development of generic versions of medications such as alpha methyldopa, an aging population, and rising rates of obesity.

The alpha (a) methyldopa market size is expected to see rapid growth in the next few years. It will grow to $15.14 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to several factors, improvements in diagnostic techniques, the expansion of public health campaigns, increased research funding, development of healthcare infrastructure, and a rise in hypertension cases. Major trends expected during this period include advancements in drug delivery systems, innovations in biopharmaceuticals, developments in clinical trial methodologies, the integration of digital health solutions, and the application of artificial intelligence in healthcare.

The a-methyldopa market is poised for growth due to increasing cases of hypertension. Hypertension, or high blood pressure, results from factors such as poor diet, lack of physical activity, obesity, and elevated stress levels. a-Methyldopa effectively treats hypertension by lowering specific chemicals in the blood, promoting blood vessel relaxation and reducing blood pressure. For example, the Heart Foundation reported in January 2024 that about 23% of adults in Australia have hypertension, with a higher prevalence among men (25%) than women (22%). This trend is expected to drive demand for a-methyldopa.

The a-methyldopa market is also expected to expand due to the growing preference for generic drugs. Generic medications are cost-effective alternatives to brand-name drugs, offering equivalent quality, performance, and safety. a-Methyldopa, as a widely used generic medication for hypertension management, particularly benefits groups such as pregnant women. The U.S. Food and Drug Administration noted in 2023 that generics constitute approximately 90% of the prescription drug market volume in the U.S., reflecting widespread adoption also seen in countries such as the U.K., Australia, China, and Germany. This preference for generics is anticipated to bolster the a-methyldopa market.

The a-methyldopa market is expected to grow due to rising healthcare expenditure. Healthcare expenditure, encompassing spending on healthcare goods and services, is increasing globally due to aging populations, higher incidence of chronic diseases, and greater demand for healthcare services and medications. For instance, in the UK, healthcare spending rose to $363.44 billion (£280.7 billion) in 2021, with an average expenditure of $5422 (£4,188) per person. This increased funding for healthcare services is set to drive demand for a-methyldopa and other hypertension treatments, underscoring its growth potential in the market.

Major companies operating in the alpha (a) methyldopa market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis International AG, Abbott Laboratories, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan N.V., Bausch Health Companies Inc., Intas Pharmaceuticals Ltd., Apotex Inc., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Laboratoires Confab, Globela Pharma Pvt. Ltd., Pro Doc Ltee, AA Pharma inc., LGM Pharma

North America was the largest region in the a-Methyldopa market in 2023. The regions covered in the alpha (a) methyldopa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha (a) methyldopa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha (a) methyldopa market consists of sales of extended-release tablets, and combination tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha (a) Methyldopa Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha (a) methyldopa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for alpha (a) methyldopa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha (a) methyldopa market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Alpha (a) Methyldopa Market Characteristics

3. Alpha (a) Methyldopa Market Trends And Strategies

4. Alpha (a) Methyldopa Market - Macro Economic Scenario

5. Global Alpha (a) Methyldopa Market Size and Growth

6. Alpha (a) Methyldopa Market Segmentation

7. Alpha (a) Methyldopa Market Regional And Country Analysis

8. Asia-Pacific Alpha (a) Methyldopa Market

9. China Alpha (a) Methyldopa Market

10. India Alpha (a) Methyldopa Market

11. Japan Alpha (a) Methyldopa Market

12. Australia Alpha (a) Methyldopa Market

13. Indonesia Alpha (a) Methyldopa Market

14. South Korea Alpha (a) Methyldopa Market

15. Western Europe Alpha (a) Methyldopa Market

16. UK Alpha (a) Methyldopa Market

17. Germany Alpha (a) Methyldopa Market

18. France Alpha (a) Methyldopa Market

19. Italy Alpha (a) Methyldopa Market

20. Spain Alpha (a) Methyldopa Market

21. Eastern Europe Alpha (a) Methyldopa Market

22. Russia Alpha (a) Methyldopa Market

23. North America Alpha (a) Methyldopa Market

24. USA Alpha (a) Methyldopa Market

25. Canada Alpha (a) Methyldopa Market

26. South America Alpha (a) Methyldopa Market

27. Brazil Alpha (a) Methyldopa Market

28. Middle East Alpha (a) Methyldopa Market

29. Africa Alpha (a) Methyldopa Market

30. Alpha (a) Methyldopa Market Competitive Landscape And Company Profiles

31. Alpha (a) Methyldopa Market Other Major And Innovative Companies

32. Global Alpha (a) Methyldopa Market Competitive Benchmarking

33. Global Alpha (a) Methyldopa Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alpha (a) Methyldopa Market

35. Alpha (a) Methyldopa Market Future Outlook and Potential Analysis

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â